Muscular Dystrophy Trial, Recruiting NCT03058185 Sponsor: Pitié-Salpêtrière Hospital Condition: Muscular Dystrophy
Back to Muscular Dystrophy

Muscular Dystrophy Trial, Recruiting

NCT03058185
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have a confirmed harmful mutation in the LMNA and/or EMD gene.
  • You are regularly seen by a doctor or medical team in France.
  • You are willing to sign a consent form agreeing to take part in the trial.

Who may not be able to join:

  • You do not wish to sign the consent form to take part in the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Karim Wahbi, MD, PhD, Assistance Publique - Hôpitaux de Paris

Phone: +33142165873

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Pitié-Salpêtrière Hospital
Registry
ClinicalTrials.gov
Start date
11 July 2013
Est. completion
11 July 2033

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Comprehensive clinical evaluation of individuals with geneticaly proven mutations in LMNA or EMD genes according to the study protocol, in order to evaluate disease progression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov